Resources from the same session
LBA12 - eMouvoir: Randomised phase III trial evaluating the impact of a personalized and remote physical activity (PA) for breast cancer survivors (BCS). Results on the quality of life (QoL)
Presenter: Laurence Vanlemmens
Session: Proffered paper session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
232O - Effects of a high-intensity exercise intervention on recurrence and survival: The OptiTrain breast cancer trial
Presenter: Helene Rundqvist
Session: Proffered paper session: Breast cancer, early stage
Resources:
Abstract
Webcast
Q&A
Session: Proffered paper session: Breast cancer, early stage
Resources:
Webcast
LBA10 - Primary endpoint results of the Neo-CheckRay phase II trial evaluating stereotactic body radiation therapy (SBRT) +/- durvalumab (durva) +/- oleclumab (ole) combined with neo-adjuvant chemotherapy (NACT) for early-stage, high risk ER+/HER2- breast cancer (BC)
Presenter: Alex De Caluwe
Session: Proffered paper session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
LBA11 - Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs)
Presenter: Iris Nederlof
Session: Proffered paper session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
LBA13 - Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial
Presenter: Peter A. Fasching
Session: Proffered paper session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA10, LBA11 and LBA13
Presenter: Elgene Lim
Session: Proffered paper session: Breast cancer, early stage
Resources:
Slides
Webcast
Q&A
Session: Proffered paper session: Breast cancer, early stage
Resources:
Webcast